Introduction
============

On account of its high morbidity and mortality, intracerebral hemorrhage (ICH) is a worldwide public health concern ([@ref-31]). About 2 million people experience ICH every year, and its incidence is still rising ([@ref-22]; [@ref-30]). Half of patients die within a year, and two-third of the survivors become permanently disabled ([@ref-9]). The poor prognosis of patients with ICH is mainly related to its complex pathogenesis. The pathological process of ICH can be divided into primary injury, which consists of mechanical compression caused by hematoma, and secondary injury, which is caused by various factors such as cytotoxicity of blood, hypermetabolism, excitotoxicity, oxidative stress and inflammation ([@ref-3]). Several studies have shown that treatments targeting the ICH-induced cellular processes and their downstream molecules may be effective ([@ref-29]).

According to previous reports, the cytokines released by various inflammatory cells such as leukocytes, macrophages, and microglia after the onset of ICH were involved in the formation of secondary brain injury caused by ICH ([@ref-41]). For example, microglia/macrophages activated after the ICH event can cause an increase in the expression levels of TNF-a and IL-1*β*, which can aggravate brain damage ([@ref-2]; [@ref-40]). In the ICH model constructed by animals, the expression of TNF-*α* was significantly increased, which promoted the formation of cerebral edema ([@ref-14]). Toll-like receptors (TLRs) play an irreplaceable role in the regulation of immune responses and inflammatory responses ([@ref-1]; [@ref-37]). TLRs are a family of transmembrane proteins, and it has been reported in the literature that the significant increase in expression levels of TLR2 and TLR4 in peripheral monocytes of ICH patients is significantly associated with poor prognosis in patients ([@ref-33]). In addition, the increased expression levels of proinflammatory genes such as CD36, iNOS, and MMP-9 all aggravated the pathological progression of ICH ([@ref-46]; [@ref-47]). Therefore, we have reason to speculate that there should be many potential genes in the pathological process of ICH that may play important regulatory roles. However, the expression profile and function of mRNAs in the course of ICH have not yet been fully explained.

Presently, research on ICH treatment has mostly focused on the clinical aspects of therapeutic interventions, and investigations into the molecular mechanisms underlying the pathology of ICH remain scarce ([@ref-44]). Therefore, identifying the therapeutic targets for ICH at the molecular level may improve the existing treatment strategies for ICH. Although previous reports by [@ref-34] on the expression profile of mRNAs have revealed the differentially expressed genes (DEGs) in the pathology of ICH, the main focus of the study was on the top ten up-regulated genes and ten down-regulated genes with the difference of the largest fold change. However, their research ignores the interaction between DEGs, which is crucial to understanding the biological significance of DEGs.

Our current research goal is to explore the expression profiles of mRNAs in ICH patients to screen for hub genes through the PPI network and subsequently analyze their functions. Furthermore, the rat model of ICH has been established to verify the expression level of hub genes by RT-qPCR. In addition, the DEGs were analyzed using the CMap tool to identify small-molecule compounds with potential therapeutic effects on ICH.

Materials & Methods
===================

Data collection
---------------

The gene expression profiles of patients with ICH were obtained from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) ([@ref-6]), a public database for researchers. [GSE24265](GSE24265), which includes the data from four spontaneous cases of intracerebral hemorrhage, relied on the Agilent GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array). All brain tissue samples were from four patients with spontaneous intracerebral hemorrhage who were diagnosed within the previous four days, including two men and two women, with a median age of 79 years (68--92 years), and all samples were obtained within 5 h of the patients' death. Perihematomal areas were used for the disease groups, while the contralateral grey and white matter were used as controls ([@ref-34]).

Screening results of DEGs
-------------------------

We downloaded the series matrix file dataset of [GSE24265](GSE24265), and subsequently transformed the gene probes of the platform to gene names by referencing the GPL570 platform. Both the normalization of the data and screening of the DEGs were performed using the limma package in the R language (version 3.5.1) ([@ref-12]). To identify the genes with significant differences in the fold change of expression, we set the screening criteria to filter genes with a fold change (FC) value of (\|log2FC\|) \> 2 and a *P*-value of \< 0.05.

GO and KEGG pathway analyses for identification of DEGs
-------------------------------------------------------

To enable better recognition of the biological functions of DEGs, we used online tools to perform GO enrichment and KEGG analyses. Based on the description of the GO analysis, the gene function annotations were identified as biological processes (BP), cellular components (CC), or molecular functions (MF). DAVID (<https://david.ncifcrf.gov/>) and KOBAS (version 3.0; <https://bio.tools/kobas>) are considered versatile bioinformatics tools; their main functions include gene annotation, visualization, identification of signaling pathways, and integrated functional discovery. Functional annotation analysis of the DEGs was performed using DAVID, and the KEGG-assisted cell signaling pathway analysis of the DEGs was carried out using KOBAS ([@ref-38]). *P*-values of \< 0.05 were considered to be statistically significant.

Construction of the PPI network and identification of hub genes
---------------------------------------------------------------

STRING is a public database that contains interactions between known and predicted proteins (<https://string-db.org/>) ([@ref-36]). PPI is essential for studying protein function since it can help elucidate the function of regulation among proteins. We uploaded the DEGs obtained from the [GSE24265](GSE24265) dataset onto STRING's official website to obtain the interrelationships between proteins and to set the minimum required interaction score to 0.15 to visualize the interaction networks with Cytoscape (version 3.2.1) ([@ref-35]). The screening of hub genes was based on the degree of connectivity between DEGs and genes; the DEGs featuring the ten highest degrees were recognized as hub genes.

Obtaining small-molecule compounds for the treatment of ICH by CMap analysis
----------------------------------------------------------------------------

CMap is a gene-expression-based drug development system that explains associations among genes, drugs, and diseases by integrating the effects of thousands of small-molecule drugs on various human cells ([@ref-23]). In this study, we converted the DEGs into probes and subsequently uploaded them onto the official website of CMap to obtain corresponding small-molecule compounds. The negatively related drugs (*P* \< 0.01 and enrichment \< 0) were considered to be therapeutically effective for treating ICH.

Rat model of ICH
----------------

All animals used in this study were tested according to the Guide for Animal Experimentation of Harbin Medical University, and the animal study approved by the Institutional Animal Care and Use Committee at Harbin Medical University. Six adult male Sprague-Dawley rats, weighing 200--250 g, aged 8 weeks, provided by the Animal Experimental Center, Harbin Medical University, were used in the present study. The animals, fixed using a stereotaxic frame, were intraperitoneally injected with sodium pentobarbital (50 mg/kg), and, using a skull drill (about one mm in diameter), holes were drilled near the right coronal suture, 3.5 mm outside the midline. Autologous whole blood (50 µL) was collected from the tail vein using a sterile disposable syringe, and, using the same syringe, the collected autologous blood was slowly injected into the right basal ganglia at a rate of 10 µl/min ([@ref-13]). After ten minutes, the syringe was pulled out and the skin was sutured. Six rats were equally divided into experimental and control groups, but the control group only received a needle insertion. All rats were intraperitoneally injected with a lethal dose of sodium pentobarbital 24 h after the surgery, and two-mm thick brain tissue surrounding the path of the injection needle was collected and stored at −80 °C until use. All animal experiments conformed to the European Parliament Directive (2010/63/EU) and were approved by the Institutional Animal Care and Use Committee at Harbin Medical University (No. HMUIRB-2008-06).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis
-------------------------------------------------------------------------------

Total RNA from the brain tissue of rats was extracted using Tri®-Reagent (Sigma, USA) according to the manufacturer's instructions. The quality and quantity of the RNA was detected using a NanoDrop One spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcription of the extracted total RNA into cDNA was performed using the Transcriptor First Stand cDNA Synthesis Kit (Roche, Indianapolis, IN, USA). RT-qPCR was performed using the FastStart Universal SYBR® Green Master (ROX) (Roche, Penzberg, Germany) and quantified using the QuantStudio software (Thermo Fisher Scientific, Waltham, MA, USA) according the manufacturer's instructions. *GAPDH* was used as the endogenous reference gene. The sequence of all primers used in this study is provided in [Table S1](#supp-3){ref-type="supplementary-material"}. The expression level of all mRNAs was determined using the 2^−Δ*CT*^ method. A meaningful analysis between the two groups was performed by a paired *t*-test, and a *P*-value \< 0.05 was considered statistically significant.

Results
=======

Identification of DEGs in ICH
-----------------------------

The gene expression profile of the [GSE24265](GSE24265) dataset contained data obtained from four perihematomal tissues and seven contralateral tissues ([Table 1](#table-1){ref-type="table"}). The result of the normalization of data among the arrays of the series matrix files of the [GSE24265](GSE24265) dataset is shown in [Fig. S1](#supp-2){ref-type="supplementary-material"}. Using a *P*-value of \< 0.05 and a \[logFC\] of \>2 as the cut-off, a total of 67 DEGs, including 59 up-regulated and 8 down-regulated genes, were obtained on comparison of the expression profiles between the cerebral hemorrhage and control groups ([Table 2](#table-2){ref-type="table"}). Volcano plots and heat maps for the distribution of DEGs were generated using R software ([Figs. 1A](#fig-1){ref-type="fig"} and [1B](#fig-1){ref-type="fig"}).

Functional annotation analysis of DEGs using GO
-----------------------------------------------

On GO analysis, the three most significant processes identified among the annotations of BP were inflammatory response, neutrophil chemotaxis, and immune response. In parallel, the three most significant processes identified among the annotations of MF were chemokine activity, CXCR chemokine receptor binding, and growth factor activity. Finally, the three most significant processes identified among the annotations of CC were extracellular space, extracellular region, and plasma membrane. According to the criteria, the results of all meaningful functional annotation analyses are summarized in [Table 3](#table-3){ref-type="table"} and [Fig. 2](#fig-2){ref-type="fig"}.
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###### Details for GEO ICH data.

![](peerj-07-7782-g007)

  **Reference**   **Sample**   **GEO**                **Platform**       **PH**   **CW**   **CG**
  --------------- ------------ ---------------------- ------------------ -------- -------- --------
  [@ref-34]       Brain        [GSE24265](GSE24265)   [GPL570](GPL570)   4        4        3

**Notes.**

PHperihematomal areaCWcontralateral white matterCGcontralateral grey matter
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###### Screening DEGs in ICH by integrated microarray.

![](peerj-07-7782-g008)

  DEGs            Gene terms
  --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     CXCL8, CCL20, C15orf48, CXCL1, VMP1, AGPAT9, G0S2, CXCL3, PTX3, TFPI2, CYTIP, TNFAIP3, PPBP, HSPA6, BCL2A1, TREM1, CCL4, IL18RAP, PMAIP1, SERPINE1, HBD, TGFBI, PNP, SELE, TIMP1, IL6, NCF2, PLAUR, LAPTM5, TCIRG1, OLR1, HBB, DUSP5, ISG20,S100P, PROK2, METRNL, CTGF, CD93,HCAR3, ANXA2P2, C5AR1, TLR2, FGR,MARCO, HMOX1, TUBB6, CYB5R2 ADM, UPP1, SLC2A3, CD163, BCAT1,CLEC5A, CCL8, HLA-DRA, TNFRSF12A,ANXA2, S100A11.
  Downregulated   NXPH1, PRRT2, SLITRK5, SOWAHA, CNTN3, CACNA2D3, MUM1L1, ZNRF3.

![Comparison of DEGs present in ICH and normal samples.\
(A) The volcano plot for DEGs in [GSE24265](GSE24265) data. *X*-axes index the -log (*P*-value) and *y*-axes index the log fold change. The red dots represent upregulated genes and the green dots represent downregulated genes. The black dots represent genes with no significant difference. FC is the fold change. (B) The expression data is represented as a data matrix wherein each row represents a gene and each column represents a sample. The blue coded bar above the heat map represents the normal sample set and the red coded bar represents the perihematomal sample. The expression level is described in terms of the color ratio of the upper left corner. Hierarchical clustering is shown by the top tree view, indicating the degree of relatedness in gene expression. Abbreviations: DEG, differentially expressed genes; ICH, intracerebral hemorrhage; FC, fold change.](peerj-07-7782-g001){#fig-1}
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###### Top 10 of the most significantly enriched GO terms.

![](peerj-07-7782-g009)

  Pathway ID   Terms                                             Gene count   *P*-value
  ------------ ------------------------------------------------- ------------ -----------
  BP                                                                          
  GO:0006954   Inflammatory response                             16           5.41E−12
  GO:0030593   Neutrophil chemotaxis                             8            4.33E−09
  GO:0006955   Immune response                                   13           3.67E−08
  GO:0070098   Chemokine-mediated signaling pathway              7            2.35E−07
  GO:0006935   Chemotaxis                                        7            5.73E−06
  GO:0001525   Angiogenesis                                      8            1.75E−05
  GO:0032496   Response to lipopolysaccharide                    7            3.10E−05
  GO:0090023   Positive regulation of neutrophil chemotaxis      4            7.02E−05
  GO:0071347   Cellular response to interleukin-1                5            1.36E−04
  GO:0045765   Regulation of angiogenesis                        4            2.00E−04
  CC                                                                          
  GO:0005615   Extracellular space                               19           5.27E−07
  GO:0005576   Extracellular region                              19           6.79E−06
  GO:0005886   Plasma membrane                                   27           9.38E−04
  GO:0005604   Basement membrane                                 4            2.70E−03
  GO:0005887   Integral component of plasma membrane             13           3.43E−03
  GO:0070062   Extracellular exosome                             19           6.75E−03
  GO:0009986   Cell surface                                      7            1.18E−02
  GO:0031093   Platelet alpha granule lumen                      3            1.60E−02
  GO:0031012   Extracellular matrix                              5            2.02E−02
  GO:0030666   Endocytic vesicle membrane                        3            2.25E−02
  MF                                                                          
  GO:0008009   Chemokine activity                                7            2.25E−02
  GO:0045236   CXCR chemokine receptor binding                   3            2.25E−02
  GO:0008083   Growth factor activity                            5            2.25E−02
  GO:0002020   Protease binding                                  4            2.25E−02
  GO:0004872   Receptor activity                                 5            2.25E−02
  GO:0048306   Calcpium-dependent protein binding                3            2.25E−02
  GO:0008329   Signaling pattern recognition receptor activity   2            2.25E−02
  GO:0001849   Complement component C1q binding                  2            2.25E−02
  GO:0005102   Receptor binding                                  5            2.25E−02
  GO:0004859   Phospholipase inhibitor activity                  2            2.25E−02

**Notes.**

GOGene OntologyBPbiological progressCCcellular componentMFmolecular function

![Results of GO enrichment.\
The abscissa represents the enriched GO, and the ordinate represents the number and ratio of the differentially expressed genes. Different colors represent different GO classes: Molecular function, Biological process, and Cellular component. Abbreviation: GO, gene ontology.](peerj-07-7782-g002){#fig-2}

KEGG pathway analysis of DEGs
-----------------------------

The results of the cell signaling pathway enrichment analysis of the DEGs identified a total of 29 meaningful pathways which were analyzed. The cellular signaling pathways clearly associated with brain damage included those for HIF-1, TNF, toll-like receptor, the NF-kappa B signaling pathway, cytokine-cytokine receptor interaction, and chemokine signaling pathways. The specific enriched pathways obtained from the analysis of the DEGs are summarized in [Table 4](#table-4){ref-type="table"} and [Fig. 3](#fig-3){ref-type="fig"}.
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###### Significantly enriched KEGG pathway.

![](peerj-07-7782-g010)

  Pathway ID   Terms                                                        Gene count   *P*-Value   Genes
  ------------ ------------------------------------------------------------ ------------ ----------- -------------------------------------------------------------------------
  hsa04060     Cytokine-cytokine receptor interaction                       10           1.59E−09    *CCL4, CCL8, CXCL8, CCL20, TNFRSF12A, IL18RAP, CXCL3, PPBP, CXCL1, IL6*
  hsa05323     Rheumatoid arthritis                                         7            3.50E−09    *TCIRG1, CXCL8, CCL20, TLR2, CXCL1, HLA-DRA, IL6*
  hsa05134     Legionellosis                                                6            9.62E−09    *CXCL8, TLR2, CXCL3, CXCL1, IL6, HSPA6*
  hsa04062     Chemokine signaling pathway                                  8            3.28E−08    *CCL4, CCL8, CXCL8, CCL20, FGR, CXCL3, PPBP, CXCL1*
  hsa04145     Phagosome                                                    7            1.45E−07    *TCIRG1, OLR1, NCF2, TLR2, TUBB6, HLA-DRA, MARCO*
  hsa05144     Malaria                                                      5            2.19E−07    *IL6, CXCL8, HBB, SELE, TLR2*
  hsa04668     TNF signaling pathway                                        6            5.37E−07    *TNFAIP3, CCL20, CXCL3, SELE, CXCL1, IL6*
  hsa05132     Salmonella infection                                         5            3.30E−06    *CXCL1, CCL4, IL6, CXCL3, CXCL8*
  hsa04621     NOD-like receptor signaling pathway                          4            1.78E−05    *CXCL1, IL6, TNFAIP3, UPP1*
  hsa05321     Inflammatory bowel disease (IBD)                             4            2.43E−05    *HLA-DRA, IL6, IL18RAP, TLR2,*
  hsa04064     NF-kappa B signaling pathway                                 4            1.04E−04    *CCL4, TNFAIP3, BCL2A1, CXCL8*
  hsa05143     African trypanosomiasis                                      3            1.09E−04    *IL6, HBB, SELE*
  hsa05146     Amoebiasis                                                   4            1.36E−04    *CXCL1, IL6, CXCL8, TLR2*
  hsa04933     AGE-RAGE signaling pathway in diabetic complications         4            1.52E−04    *IL6, SERPINE1, SELE, CXCL8*
  hsa04066     HIF-1 signaling pathway                                      4            1.63E−04    *IL6, SERPINE1, TIMP1, HMOX1*
  hsa05142     Chagas disease (American trypanosomiasis)                    4            1.69E−04    *IL6, CXCL8, SERPINE1, TLR2*
  hsa04620     Toll-like receptor signaling pathway                         4            1.81E−04    *CCL4, IL6, CXCL8, TLR2*
  hsa05162     Measles                                                      4            4.47E−04    *IL6, TNFAIP3, HSPA6, TLR2*
  hsa05120     Epithelial cell signaling in Helicobacter pylori infection   3            7.57E−04    *CXCL1, TCIRG1, CXCL8*
  hsa05140     Leishmaniasis                                                3            8.21E−04    *HLA-DRA, NCF2, TLR2*
  hsa05152     Tuberculosis                                                 4            1.04E−03    *TCIRG1, IL6, HLA-DRA, TLR2*
  hsa05164     Influenza A                                                  4            1.06E−03    *HLA-DRA, IL6, HSPA6, CXCL8*
  hsa04610     Complement and coagulation cascades                          3            1.15E−03    *C5AR1, PLAUR, SERPINE1*
  hsa05169     Epstein-Barr virus infection                                 4            1.85E−03    *HLA-DRA, FGR, TNFAIP3, HSPA6*
  hsa05145     Toxoplasmosis                                                3            3.57E−03    *HLA-DRA, HSPA6, TLR2*
  hsa05332     Graft-versus-host disease                                    2            4.53E−03    *HLA-DRA, IL6*
  hsa04672     Intestinal immune network for IgA production                 2            6.46E−03    *HLA-DRA, IL6*
  hsa05161     Hepatitis B                                                  3            6.47E−03    *IL6, CXCL8, TLR2*
  hsa05150     Staphylococcus aureus infection                              2            8.12E−03    *HLA-DRA, C5AR1*

**Notes.**

KEGGKyoto Encyclopedia of Genes and Genomes

![KEGG pathway analysis of the differentially expressed genes in ICH.\
Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; ICH, intracerebral hemorrhage.](peerj-07-7782-g003){#fig-3}

PPI network construction and hub gene identification
----------------------------------------------------

We uploaded 67 DEGs to the string online database to obtain the PPI network. A total of 57 DEGs were consequently extracted among the 67 DEGs uploaded when the interaction score was set to 0.15. The resulting PPI network contained a total of 57 nodes and 373 edges. [Figure 4A](#fig-4){ref-type="fig"} presents the visualization of the network generated using Cytoscape software; [Figure 4B](#fig-4){ref-type="fig"} represents the ten selected hub genes with the highest degrees of connectivity that were selected as the hub genes. Prior reports indicate that the identified hub genes are closely related to ICH and brain damage. The subsequent GO function annotation analysis and KEGG pathway analysis results for hub genes are summarized in [Tables 5](#table-5){ref-type="table"} and [6](#table-6){ref-type="table"}.

![PPI network analysis.\
(A) Using the STRING online database, a total of 57 DEGs (56 upregulated \[red\] and one downregulated gene \[green\]) were filtered into the DEG PPI network. (B) Of the DEGs with more than ten edges in the PPI network, the ten with the highest degrees of connectivity were selected as the hub genes; all are upregulated genes. Abbreviations: PPI, protein--protein interaction; DEGs, differentially expressed genes.](peerj-07-7782-g004){#fig-4}
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###### Significantly enriched GO of hub genes.

![](peerj-07-7782-g011)

  **ID**       **Description**                                        ***P*-value**   **Count**   **Gene names**
  ------------ ------------------------------------------------------ --------------- ----------- ---------------------------------------------------------------
  **BP**                                                                                          
  GO:0009611   Response to wounding                                   4.58E−11        9           CXCL1/ IL6/ CCL20/ SERPINE1/ TLR2/ SELE/ CCL4/ PLAUR/ CD163.
  GO:0006954   Inflammatory response                                  1.45E−08        7           CXCL1/ IL6/ CCL20/ TLR2/ SELE/ CCL4/ CD163.
  GO:0006952   Defense response                                       6.44E−07        7           CXCL1/ IL6/ CCL20/ TLR2/ SELE/ CCL4/ CD163.
  GO:0042330   Taxis                                                  2.27E−06        5           CXCL1/ IL6/ CCL20/ CCL4/ PLAUR.
  GO:0006935   Chemotaxis                                             2.27E−06        5           CXCL1/ IL6/ CCL20/ CCL4/ PLAUR.
  GO:0006955   Immune response                                        2.25E−04        4           CXCL1/ IL6/ CCL20/ TLR2/ CCL4.
  GO:0007596   Blood coagulation                                      6.88E−04        5           IL6/ SERPINE1/ PLAUR.
  GO:0050817   Coagulation                                            0.001396979     3           IL6/ SERPINE1/ PLAUR.
  GO:0007599   Hemostasis                                             0.001957914     3           IL6/ SERPINE1/ PLAUR.
  GO:0042742   Defense response to bacterium                          0.001957914     3           IL6/ CCL20/ TLR2.
  GO:0006928   Cell motion                                            0.002191691     3           IL6/ SELE/ CCL4/ PLAUR.
  GO:0050878   Regulation of body fluid levels                        0.002354575     3           IL6/ SERPINE1/ PLAUR.
  GO:0032101   Regulation of response to external stimulus            0.003084628     4           IL6/ SERPINE1/ SELE.
  GO:0042060   Wound healing                                          0.003701403     3           IL6/ SERPINE1/ PLAUR.
  GO:0032755   Positive regulation of interleukin-6 production        0.004681351     3           IL6/ TLR2.
  GO:0042127   Regulation of cell proliferation                       0.006688038     3           CXCL1/ IL6/ SERPINE1/ TIMP1.
  GO:0042246   Tissue regeneration                                    0.012573365     2           SERPINE1/ PLAUR.
  GO:0032675   Regulation of interleukin-6 production                 0.012647695     4           IL6/ TLR2.
  GO:0006953   Acute-phase response                                   0.02109503      2           IL6/ CD163.
  GO:0030162   Regulation of proteolysis                              0.023703896     2           PLAUR/ TIMP1.
  GO:0050900   Leukocyte migration                                    0.02630658      2           IL6/ SELE.
  GO:0051091   Positive regulation of transcription factor activity   0.034722761     2           IL6/ TLR2.
  GO:0045765   Regulation of angiogenesis                             0.037299313     2           IL6/ SERPINE1.
  GO:0031099   Regeneration                                           0.039227714     2           SERPINE1/ PLAUR.
  GO:0043388   Positive regulation of DNA binding                     0.04115268      2           IL6/ TLR2.
  GO:0031349   Positive regulation of defense response                0.044992331     2           IL6/ TLR2.
  GO:0050727   Regulation of inflammatory response                    0.049454644     2           IL6/ SELE.
  **CC**                                                                                          
  GO:0009611   Extracellular region                                   2.86E−06        9           CXCL1/ IL6/ CCL20/ SERPINE1/ SELE/ CCL4/ PLAUR/ CD163/ TIMP1.
  GO:0006954   Extracellular region part                              2.31E−04        6           CXCL1/ IL6/ CCL20/ SELE/ CCL4/ TIMP1.
  GO:0006952   Extracellular space                                    8.30E−04        5           CXCL1/ IL6/ CCL20/ SELE/ CCL4.
  **MF**                                                                                          
  GO:0005125   Cytokine activity                                      2.62E−04        4           CXCL1/ IL6/ CCL20/ CCL4.
  GO:0008009   Chemokine activity                                     4.35E−04        3           CXCL1/ CCL20/ CCL4.
  GO:0042379   Chemokine receptor binding                             4.94E−04        3           CXCL1/ CCL20/ CCL4.
  GO:0019899   Enzyme binding                                         0.048323907     3           SERPINE1/ SELE/ PLAUR.

**Notes.**

GOGene OntologyBPbiological progressCCcellular componentMFmolecular function
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###### Significantly enriched KEGG pathway of hub genes.

![](peerj-07-7782-g012)

  Pathway ID   Terms                                          Gene count   *P*-Value     Genes
  ------------ ---------------------------------------------- ------------ ------------- ----------------------------
  hsa04668     TNF signaling pathway                          4            5.54E−08      *CXCL1, CCL20, IL6, SELE.*
  hsa04066     HIF-1 signaling pathway                        3            6.38E−06      *IL6, SERPINE1, TIMP1.*
  hsa04060     Cytokine-cytokine receptor interaction         3            9.63E−05      *CXCL1, CCL20, IL6.*
  hsa04621     NOD-like receptor signaling pathway            2            0.000199993   *CXCL1,IL6.*
  hsa04610     Complement and coagulation cascades            2            0.000364662   *SERPINE1,PLAUR.*
  hsa04620     Toll-like receptor signaling pathway           2            0.000671108   *IL6,TLR2.*
  hsa04062     Chemokine signaling pathway                    2            0.00200085    *CXCL1,CCL20.*
  hsa04151     PI3K-Akt signaling pathway                     2            0.006358451   *IL6,TLR2.*
  hsa04672     Intestinal immune network for IgA production   1            0.016724268   *IL6*
  hsa04623     Cytosolic DNA-sensing pathway                  1            0.022711959   *IL6*
  hsa04115     p53 signaling pathway                          1            0.02481751    *SERPINE1*
  hsa01521     EGFR tyrosine kinase inhibitor resistance      1            0.029714789   *IL6*
  hsa04068     FoxO signaling pathway                         1            0.047713858   *IL6*

**Notes.**

KEGGKyoto Encyclopedia of Genes and Genomes

CMap analysis
-------------

We used CMap to analyze the previously selected DEGs and to identify small-molecule compounds with potential therapeutic application in ICH cases. Nine small-molecule compounds which exhibited high correlation with ICH are shown in [Table 7](#table-7){ref-type="table"}. The three-dimensional chemical structures of the small-molecule compounds hecogenin, lidocaine, and NU-1025, previously reported to be significantly associated with brain damage, are shown in [Fig. 5](#fig-5){ref-type="fig"}.
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###### Results of CMap analysis.

![](peerj-07-7782-g013)

  Rank   CMap name        Mean     *N*   Enrichment   *P*-value
  ------ ---------------- -------- ----- ------------ -----------
  1      Hecogenin        −0.613   4     −0.931       0.00002
  2      Pralidoxime      −0.529   4     −0.872       0.00056
  3      Metolazone       −0.282   5     −0.779       0.00096
  4      Lidocaine        −0.258   5     −0.766       0.0013
  5      NU-1025          −0.579   2     −0.956       0.00414
  6      Ambroxol         −0.269   4     −0.774       0.00527
  7      Pipemidic acid   −0.336   3     −0.846       0.00735
  8      Yohimbic acid    −0.345   3     −0.845       0.00747
  9      Chlorphenesin    −0.354   4     −0.74        0.00899

**Notes.**

CMapConnectivity Map

![The 3D conformers of the three compounds that may attenuate secondary injury after hematoma.\
(A) Hecogenin, (B) Lidocaine, (C) NU-125. The 3D structures of the nine compounds were provided by PubChem (<https://pubchem.ncbi.nlm.nih.gov/compound>).](peerj-07-7782-g005){#fig-5}

Corroboration of ten hub genes using RT-qPCR
--------------------------------------------

RT-qPCR was performed with the total RNA extracted from the brain tissue of three pairs of rats used for the ICH model to confirm the expression levels of ten hub genes. According to the PPI network analysis, the ten core genes screened were *IL6*, *TLR2*, *CXCL1*, *TIMP1*, *PLAUR*, *SERPINE1*, *SELE*, *CCL4*, *CCL20*, and *CD163*. The expression levels of the ten hub genes were increased as part of the pathophysiological process of ICH. The results of the RT-qPCR experiment showed a significant increase in the expression of the hub genes ([Fig. 6](#fig-6){ref-type="fig"}).

![Relative expression of the ten hub genes including (A) IL6, (B) TLR2, (C) CXCL1, (D) TIMP1, (E) PLAUR, (F) SERPINE1, (G) SELE, (H) CCL4, (I) CCL20, and (J) CD163 measured by RT-qPCR.](peerj-07-7782-g006){#fig-6}

Discussion
==========

The present study uses the GEO database to obtain gene expression profiles from patients with ICH and screens for DEGs. We perform functional enrichment analyses on the obtained DEGs to understand their biological functions. Meanwhile, we report meaningful enrichment, by KEGG analysis, of pathways involved in triggering the regulatory pathway associated with secondary brain injury induced by ICH. Next, PPI analyses were carried out to identify the hub genes that may play a crucial regulatory role in the pathophysiology of ICH. At the same time, we established a rat model of ICH, and confirmed that the expression level of hub genes were consistent with the results of our analyses by RT-qPCR. In addition, several potential small-molecule compounds, related to ICH, were identified by CMap analysis. These may become effective drugs for treating ICH in future.

From the [GSE24265](GSE24265) dataset, after comparing the gene expression data obtained from ICH tissue with that obtained from the contralateral brain tissues, we obtained 67 DEGs. GO analysis indicated that the main functional annotation results were consistent with those obtained by previous reports, i.e., a significant increase in inflammatory response promotes ICH-induced brain injury, which may be one of the main factors contributing to the poor prognosis in patients with ICH ([@ref-4]; [@ref-10]). The immune response can antagonize the inflammatory response, induced after an episode of cerebral hemorrhage, to reduce the secondary damage to brain tissue, and thereby improve the recovery of nerve function ([@ref-20]; [@ref-28]). Previous reports have indicated that the cellular signaling pathways identified in this study using a KEGG analysis were closely related to cerebral hemorrhage; those activated within a few hours after cerebral hemorrhage, including the TNF signaling pathway, which participates in the secondary inflammatory reactions and formation of cerebral edema around the hematoma ([@ref-39]) and the HIF-1 signaling pathway, which contributes to the recovery of neural function after ICH by regulating the proliferation and differentiation of neural stem cells ([@ref-45]). The NF-kappa B signaling pathway, which is closely related to the death of cells surrounding the hematoma in the animal ICH model, and the activation of which is associated with deficiencies in neurological function ([@ref-48]), was activated several minutes after the ICH event. The Toll-like receptor signaling pathway is significantly associated with a poor prognosis after ICH because it promotes the inflammatory response of ICH-induced brain injury ([@ref-43]). Therefore, prior reports have been able to verify the accuracy of our results.

PPI networks are essential in most biological processes, play an important role in the development of many diseases and are very useful for the identification of drug targets, therefore demonstrating great potential for drug discovery ([@ref-32]). Compared to the original article which identified ICH related genes only by multiple gene expression analyses ([@ref-34]), hub genes screened by constructing PPI networks are more relevant to the pathological processes of ICH and are more likely to be potential therapeutic targets. Therefore, we uploaded the DEGs to the STRING database to build a PPI network and further identify the hub genes that influence regulatory processes in the pathophysiology of ICH-induced brain injury. For instance, IL-6 was significantly elevated in the serum of patients with ICH, and its levels were clearly associated with Glasgow Coma Scale scores ([@ref-8]). During brain injury, IL-6 signaling may not only induce the chemotactic migration of inflammatory cells to the site of lesion but may also promote T-cell polarization ([@ref-5]). The inflammatory response plays a key role in ICH-induced brain injury, and hemoglobin causes toll-like receptors 2 and 4 to heterodimerize and aggravate brain damage ([@ref-43]). Within 24 h of having a stroke, the expression level of CXCL1 in the cerebrospinal fluid of patients positively correlates with the ischemic area, indicating that CXCL1 may participate in the regulation of brain tissue damage ([@ref-27]). The abnormal expression of TIMP1 can disrupt the integrity of the blood--brain barrier and this disruption may be involved in the regulation of the pathological process of ICH ([@ref-42]). The urokinase-type plasminogen activator, encoded by the *PLAUR* gene, is involved in the development of the neural circuit of the cortex and in brain tissue remodeling after a brain injury ([@ref-25]). A few hours after the onset of ICH, because of red blood cell fragmentation, some products released by the lysed red blood cells around the site of the hematoma were involved in secondary brain damage. In this process, CD163 and hemoglobin form a complex which participates in the pathological process of secondary brain injury induced by ICH ([@ref-26]). *SERPINE1*, *CCL4*, and *CCL20* have not yet been reported in cases of IHC, but, on review of the literature, we found that these genes are associated with nerve injury, such as sterile inflammatory reaction and traumatic brain injury, which are pathologically similar to ICH, such as sterility inflammatory reaction ([@ref-11]; [@ref-21]; [@ref-24]). These hub genes, therefore, feature as potential prognostic or diagnostic markers, as well as potential therapeutic targets.

CMap is a database that covers the interactions among diseases, gene expression patterns, and small-molecule compounds. It is often used to screen for small-molecule compounds with therapeutic effects on some diseases ([@ref-23]). Using CMap analysis, we identified nine small molecule drugs, two of which were lidocaine and NU-1025, both previously reported to have a salutary effect in cases of brain injury. Lidocaine is commonly used as a local anesthetic and has been shown to have significant anti-inflammatory effects. A recent study demonstrated that lidocaine inhibited the release of inflammatory factors and alleviated microglial damage ([@ref-18]). Moreover, lidocaine is considered to have a therapeutic effect in cases of nerve damage induced by cerebral hemorrhage. Recent studies have found that NU-1025, a poly (ADP-ribose) polymerase inhibitors, can attenuate neurological damage in animal models of ischemic stroke and traumatic brain injury; moreover, rats treated with NU1025 exhibited reduced infarction, significantly reduced edema volume, and significantly ameliorated neurological impairment ([@ref-19]). Thus, NU-1025 can both mitigate the damage inflicted in the early stages of nerve injury and reduce the degree of subsequent neuroinflammation ([@ref-7]). Although the two aforementioned drugs have been reported to be associated with the treatment of ICH, the mechanisms underlying their therapeutic actions still require further research. In addition, we found that hecogenin has an anti-inflammatory effect that may contribute to the treatment of ICH ([@ref-15]; [@ref-16]; [@ref-17]).

However, this study had several limitations. First, the mechanisms of several hub genes in the pathological process of ICH remain unclear, warranting further study. Moreover, the effectiveness of our small molecule compound screening in reducing ICH-induced brain injury remains to be assessed.

Conclusions
===========

The hub genes identified by constructing a PPI network have potential in the development of new targets in the treatment of ICH and as prognostic markers in patients with ICH. The hub genes may be involved in the pathological process of ICH and ultimately affect their prognosis through TNF signaling pathway, HIF-1 signaling pathway, NF-kappa B signaling pathway, Toll-like receptor signaling pathway and Chemokine signaling pathway. In addition, this study identified small-molecule compounds that may be efficacious in the treatment of secondary brain injury induced by ICH.
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###### Basic information of th GSE24265 expression profiling

Raw data exported from GSE24265 expression profiling applied for data analyses and preparation for [Fig. 1](#fig-1){ref-type="fig"} by using limma package in the R language.

###### 

Click here for additional data file.
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###### Box plots of normalized gene expression data

\(A\) Blue indicates that the raw data has not been standardized. (B) Red indicates that the raw data has been normalized.

###### 

Click here for additional data file.
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###### Primer sequences for ten hub genes
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Click here for additional data file.
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